Glucocorticoids and diabetes mellitus

Česká verzia

Authors: K. Vondra; R. Hampl
Authors place of work: Endokrinologický ústav, Praha, ředitel doc. MUDr. Vojtěch Hainer, CSc.
Published in the journal: Vnitř Lék 2006; 52(5): 493-497
Category: Diabetes and other subjects (infection, dermatovenerology and rheumatology) Hradec Králové 3 to 4 June 2005

Summary

Diabetogenic effect of glucocorticoids is determined by dose volume, duration of administration and structure and type of particular preparation. The effect is influenced also by the state of glucocorticoid receptors (increased sensitivity of some gene mutations, resistance syndromes) and times of year and day when glucocorticoids are administered. Development of impaired glucose tolerance or diabetes mellitus depends on the ability of islets of Langerhans to control insulin resistance induced by glucocorticoids. The compensatory function of islets of Langerhans decreases with age and that is why steroid diabetes mellitus affects mostly seniors. Besides treatment regimes and application of sulfonylurea and insulin, there are some new therapeutic methods available: thiazolidindiones, metformin, short-acting secretagogue, alpha-glucosidase, and theoretically also antiglucocorticoids. Application of insulin in type 2 diabetics is justified by the effort to prevent nonketotic hyperosmolar coma. In type 1 diabetes, it is usually necessary to increase the overall insulin dose and change its dosage during the day.

Key words:
glucocorticoids – diabetes mellitus – glucose tolerance – gluconeogenesis – insulin resistance

Zdroje

1. Dimitriadis GD, Raptis SA, Newsholme EA Integration of Some Biochemical and Physiologic Effects of Insulin That May Play a Role in the Control of Blood Glucose Concentration. In: LeRoith D, Taylor SI, Olefsky JM Diabetes Mellitus: a fundamental and clinical text. Lippincot Williams and Wilkins, 2000; 161-176.

2. Schmidt BM, Christ M, Falkenstein E et al. Nongenomic steroid actions: Completing the puzzle. Reviews. Exp Clin Endocrinol Diabetes 1998; 106: 441-445.

3. Comi RJ Drug-Induced Diabetes Mellitus. In: LeRoith D, Taylor SI, Olefsky JM (eds.) Diabetes Mellitus: a fundamental and clinical text. Lippincot Williams and Wilkins, 2000; 582-588.

4. Andrews RC, Walker BR Glucocorticoids and insulin resistance: old hormones, new targets. Clinical Sci 1999; 96: 513-523.

5. Weinstein SP, Wilson CM, Pritsker A et al. Dexamethasone inhibits insulin stimulated recruitment of GLUT 4 to the cell surface in rat skeletal muscle. Metabolism-Clinical and Experimental 1998; 47: 3-6.

6. Shepherd PR, Abel DL, Kahn BB Glucose Transporters and Pathophysiologic States. In: LeRoith D, Taylor SI, Olefsky JM (eds.) Diabetes Mellitus: a fundamental and clinical text. Lippincot Williams and Wilkins, 2000; 627-640.

7. Folli F, Saad MJA, Kahn CR Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosterodi-induced insulin resistance. Acta Diabetol 1996; 33: 185-192.

8. Ekstrand A, Saloranta C, Ahonen J et al. Reversal of Steroid-Induced Insulin Resistance by a Nicotinic-Acid Derivative in Man. Metabolism 1992; 41: 692-697.

9. Berelowitz M, Kourides IA Diabetes Mellitus Secondary to Other Endocrine Disorders. In: LeRoith D, Taylor SI, Olefsky JM (eds.) Diabetes Mellitus: a fundamental and clinical text. Lippincot Williams and Wilkins, 2000; 588-595.

10. McMahon M, Gerich J, Rizza R Effects of Glucocorticoids on Carbohydrate Metabolism. Diabetes Metab Rew 1988; 4: 19-30.

11. Nicod N, Giusti V, Besse C et al. Metabolic adaptations to dexamethazone-induced insulin resistance in healthy volunteers. Obes Res 2003, 11: 625-631.

12. Besse C, Nicod N, Tappy L Changes in insulin secretion and glucose metabolism induced by dexamethazone in lean and obese females. Obes Res 2005, 13: 306-311.

13. Grill V, Pigon J, Hartling SG et al. Effects of Dexamethasone on Glucose-Induced Insulin and Proinsulin Release in Low and High Insulin Responders. Metabolism 1990; 39: 251-258.

14. Vottero A, Chrousos GP Glucocorticoid Receptor beta: View I. TEM 1999; 10: 333-338.

15. Carlstedt-Duke J Glucocorticoid Receptor beta: View II. TEM 1999; 10: 339-341.

16. Huizenga NATM, Koper JW, De Lange P et al. A Polymorphism in the Glucocorticoid Receptor Gene May Be Associated with an Increased Sensitivity to Glucocorticoids in Vivo. J Clin Endocrinol Metab 1998; 83: 144-151.

17. Zennaro MC Syndromes of glucocorticoid and mineralocorticoid resistance. Eur J Endocrinol 1998; 139: 127-138.

18. Tesfay H, Hampl R, Stárka L Peripheral glucocorticoid resistance in the light of recent knowledge of their actions. Endocrine Regulations 1998; 32: 51-61.

19. Walker BR, Best R, Noon JP et al. Seasonal variation in glucocorticoid activity in healthy men. J Clin Endocrinol Metab 1997; 82: 4015-4019.

20. Platt L, Leproult R, L´Hermite-Baleriaux M et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999; 84: 3082-3092.

21. Binnert C, Ruchat S, Nicod N et al. Dexamethasone-induced insulin resistance shows no gender difference in healthy humans. Diabetes Metab 2004, 30: 321-326.

22. Henriksen JE, Alford F, Ward GM et al. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997; 40: 1439-1448.

23. Kahn SE, Horber FF, Prigeon RL et al. Effect of Glucocorticoid and Growth Hormone Treatment on Proinsulin Levels in Humans. Diabetes 1993; 42: 1082-1085.

24. Hollingdal M, Juhl CB, Dall R et al. Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 2002; 45: 49-55.

25. Pellacani A, Fornengo P, Bruno A et al. Acute methyprednisolone administration induces a transient alteration of glucose tolerance and pyruvate dehydrogenase in humans. Eur J Clin Invest 1999; 29: 861-867.

26. Meacham LR, Abdul-Latif H, Sullivan K et al. Predictors of Change in Insulin Sensitivity During Glucocorticoid Treatment. Horm Metab Res 1997; 29: 172-175.

27. Arizaandraca CR, Barilefabris LA, Fratimunari AC et al. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998; 29: 259-262.

28. Turpeinen M, Sorva R, Juntunen-Backman K Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol 1991; 88: 384-387.

29. Kruszynska YT, Greenstone M, Home PD Effect of high-dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax 1987; 42: 881-886.

30. Vondra K, Němcová D, Stárka L et al. Metformin příznivě ovlivnuje porušenou glykoregulaci při dlouhodobé léčbě nízkými dávkami prednisonu. Čas Lék Čes 2002; 141: 255-260.

31. Fujibayashi K, Nagasaka S, Itabashi N et al. Troglitazone Efficacy in a Subject With Glucocorticoid-Induced Diabetes. Diabetes Care 1999; 22: 2088.

32. Willi SM, Kennedy A, Brant BP et al. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 2002; 58: 87-96.

33.Willi SM, Kennedy A, Wallace P et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans. Diabetes 2002; 51: 2895-2902.

34. Vondra K, Hampl R, Němcová D et al. Vztah některých steroidů, IGF-1, IGF BP-3, a růstového hormonu ke glykoregulaci při dlouhodobé léčbě nízkými dávkami glukokortikoidů. Čas Lék Čes 2002; 141: 89-95.

35. Buffington CK, Pourmotabbed G, Kitabachi AE Case report: amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 1993; 306: 320-324.

36. Wellman M, Shane-McWhorter L, Orlando-Jennings JP The role of dehydroepiandrosterone in diabetes mellitus. Pharmacotherapy 1999; 19: 582-591.

37. Lambing CL Osteoporosis prevention, detection, treatment. Postgraduate Medicine 2000; 107: 59-67.

38. Panthakalam S, Bhatnagar D, Klimiuk P The prevalence and management of hyperglycaemia in patients with rheumatoid artritis on corticosteroid therapy. Scott Med J 2004; 49: 139-141 .